111 related articles for article (PubMed ID: 30158420)
1. [Azacitidine for Therapy-Related Myelodysplastic Syndrome Following Oxaliplatin (L-OHP)Therapy for Metastatic Rectal Cancer].
Matsui T; Sakamoto N; Doi A; Fujii T; Ohno N; Sahara N; Irie S
Gan To Kagaku Ryoho; 2018 Aug; 45(8):1201-1203. PubMed ID: 30158420
[TBL] [Abstract][Full Text] [Related]
2. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
Omatsu T; Udaka K; Shibata H; Sekimoto E; Ozaki S
Rinsho Ketsueki; 2017; 58(12):2369-2374. PubMed ID: 29332868
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Postoperative Recurrence of Rectal Cancer in Which Desensitization Therapy Was Effective against Oxaliplatin Allergy in L-OHP].
Katagiri M; Miwa K; Shimomura S; Yomoda T; Tajiri K; Nagasu S; Fujino S; Koushi K; Fujita F; Kinugasa T; Akagi Y
Gan To Kagaku Ryoho; 2018 May; 45(5):875-878. PubMed ID: 30026456
[TBL] [Abstract][Full Text] [Related]
4. [Azacitidine therapy for low-risk myelodysplastic syndrome developing after solid organ transplantation].
Inoue H; Morita Y; Rai S; Kakutani H; Ohyama Y; Taniguchi Y; Tanaka H; Shimada T; Tatsumi Y; Ashida T; Matsumura I
Rinsho Ketsueki; 2017; 58(2):138-142. PubMed ID: 28321091
[TBL] [Abstract][Full Text] [Related]
5. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T
Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
[TBL] [Abstract][Full Text] [Related]
8. Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease.
Kono M; Komeda Y; Sakurai T; Okamoto A; Minaga K; Kamata K; Hagiwara S; Inoue H; Enoki E; Matsumura I; Watanabe T; Kudo M
J Crohns Colitis; 2018 Mar; 12(4):499-502. PubMed ID: 29253109
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Adès L; Itzykson R; Fenaux P
Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
Ueda S; Miyakoshi S; Chizuka A; Kojima R; Ogasawara T; Miyamoto K
Rinsho Ketsueki; 2013 Dec; 54(12):2177-81. PubMed ID: 24452149
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
Fujimaki K; Miyashita K; Kawasaki R; Tomita N
Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
[TBL] [Abstract][Full Text] [Related]
12. [Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
Inagaki S; Tamai Y; Yoshizawa M; Sato S; Kanbe E; Tanaka E
Gan To Kagaku Ryoho; 2015 Nov; 42(11):1443-6. PubMed ID: 26602409
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Inoue A; Kawakami C; Takitani K; Tamai H
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e322-4. PubMed ID: 24608072
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
[TBL] [Abstract][Full Text] [Related]
15. Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer.
Hashimoto A; Takada K; Horiguchi H; Sato T; Iyama S; Murase K; Kamihara Y; Ono K; Tatekoshi A; Hayashi T; Miyanishi K; Sato Y; Furuhata T; Kobune M; Takimoto R; Hirata K; Kato J
Case Rep Oncol; 2014 May; 7(2):316-22. PubMed ID: 24932174
[TBL] [Abstract][Full Text] [Related]
16. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
17. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.
Tanaka H; Shimizu N; Tougasaki E; Kawajiri C; Hashimoto S; Takeda Y; Sakai S; Takeuchi M; Ohwada C; Sakaida E; Takagi T; Nakaseko C
Int J Hematol; 2013 Apr; 97(4):520-4. PubMed ID: 23519573
[TBL] [Abstract][Full Text] [Related]
20. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Suwanawiboon B; Sumida KN
Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
